Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats.
Mamazhakypov A, Weiß A, Zukunft S, Sydykov A, Kojonazarov B, Wilhelm J, Vroom C, Petrovic A, Kosanovic D, Weissmann N, Seeger W, Fleming I, Iglarz M, Grimminger F, Ghofrani HA, Pullamsetti SS, Schermuly RT. Mamazhakypov A, et al. Among authors: iglarz m. Pulm Circ. 2020 Nov 11;10(4):2045894020947283. doi: 10.1177/2045894020947283. eCollection 2020 Oct-Dec. Pulm Circ. 2020. PMID: 33240483 Free PMC article.
Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis.
Kosanovic D, Luitel H, Dahal BK, Cornitescu T, Janssen W, Danser AH, Garrelds IM, De Mey JG, Fazzi G, Schiffers P, Iglarz M, Fischli W, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Reiss I, Schermuly RT. Kosanovic D, et al. Among authors: iglarz m. Eur Respir J. 2015 Oct;46(4):1084-94. doi: 10.1183/09031936.00018215. Epub 2015 Jun 25. Eur Respir J. 2015. PMID: 26113671 Free article.
Selective improvement of pulmonary arterial hypertension with a dual ETA/ETB receptors antagonist in the apolipoprotein E-/- model of PAH and atherosclerosis.
Renshall L, Arnold N, West L, Braithwaite A, Pickworth J, Walker R, Alfaidi M, Chamberlain J, Casbolt H, Thompson AAR, Holt C, Iglarz M, Francis S, Lawrie A. Renshall L, et al. Among authors: iglarz m. Pulm Circ. 2018 Jan-Mar;8(1):2045893217752328. doi: 10.1177/2045893217752328. Epub 2017 Dec 20. Pulm Circ. 2018. PMID: 29261014 Free PMC article.
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, Studer R, Vezzali E, Freti D, Hadana H, Schläpfer M, Cattaneo C, Bortolamiol C, Weber E, Whitby BR, Delahaye S, Wanner D, Steiner P, Nayler O, Hess P, Clozel M. Iglarz M, et al. J Cardiovasc Pharmacol. 2015 Nov;66(5):457-67. doi: 10.1097/FJC.0000000000000296. J Cardiovasc Pharmacol. 2015. PMID: 26230396 Free PMC article.
The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation.
Steven S, Oelze M, Hausding M, Roohani S, Kashani F, Kröller-Schön S, Helmstädter J, Jansen T, Baum C, Iglarz M, Schulz E, Münzel T, Daiber A. Steven S, et al. Among authors: iglarz m. Oxid Med Cell Longev. 2018 Dec 27;2018:7845629. doi: 10.1155/2018/7845629. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30687454 Free PMC article.
55 results